CRNX250516C30000
- 2.50
- 0.000.00%
Crinetics Newsroom
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
Express News | Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug
Express News | Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (Maa) and Orphan Drug Designation (Odd) for Paltusotine in Acromegaly
J.P. Morgan Maintains Crinetics(CRNX.US) With Buy Rating, Announces Target Price $53
JP Morgan Survey: 90% Of Endocrinologists Are Aware Of Crinetics' Atumelnant Data
Stifel Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $60
Express News | Crinetics Pharmaceuticals Inc : JP Morgan Cuts Target Price to $53 From $57
This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Crinetics Pharmaceuticals Analyst Ratings
Stifel Initiates Crinetics(CRNX.US) With Buy Rating, Announces Target Price $60
Insider Sale: Chief Med and Dev Officer of $CRNX Sells 127 Shares
Express News | Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth
Morgan Stanley Initiates Crinetics(CRNX.US) With Buy Rating, Announces Target Price $70
Crinetics Pharma's Earnings Call: Progress Amid Challenges
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $68 to $100
Earnings Call Summary | Crinetics(CRNX.US) Q4 2024 Earnings Conference